PRAKASH MASAND to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications PRAKASH MASAND has written about Randomized Controlled Trials as Topic.
Connection Strength
0.410
-
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opin Drug Saf. 2022 Jun; 21(6):725-732.
Score: 0.126
-
Efficacy of antidepressants: bias in randomized clinical trials and related issues. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):15-25.
Score: 0.092
-
Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017 05; 29(2):92-107.
Score: 0.089
-
The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. Contemp Clin Trials. 2009 Mar; 30(2):116-22.
Score: 0.050
-
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. Ann Clin Psychiatry. 2022 02; 34(1):33-43.
Score: 0.031
-
Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. J Psychiatr Res. 2017 01; 84:292-300.
Score: 0.022